Drug Search Results
More Filters [+]

PA-5108

Alternative Names: pa-5108, pa 5108, pa5108, PA5108 Latanoprost FA SR Ocular Implant
Latest Update: 2024-04-12
Latest Update Note: Clinical Trial Update

Product Description

PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma.

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: Intraocular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PolyActiva
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PA-5108

Countries in Clinic: Australia, New Zealand

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Glaucoma, Open-Angle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LATA CS102

P1

Active, not recruiting

Glaucoma, Open-Angle

2024-09-30

21%

Recent News Events